Maze Therapeutics (NASDAQ:MAZE) Stock Price Down 5.8% After Insider Selling

Maze Therapeutics, Inc. (NASDAQ:MAZE)’s stock price fell 5.8% during trading on Monday after an insider sold shares in the company. The stock traded as low as $25.85 and last traded at $25.85. 203,386 shares changed hands during trading, a decline of 68% from the average daily volume of 642,078 shares. The stock had previously closed at $27.44.

Specifically, insider Atul Dandekar sold 7,500 shares of the stock in a transaction that occurred on Friday, August 28th. The shares were sold at an average price of $27.58, for a total value of $206,850.00. Following the completion of the transaction, the insider directly owned 26,250 shares in the company, valued at $723,975. This trade represents a 22.22% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Analyst Ratings Changes

MAZE has been the subject of several research analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Maze Therapeutics in a research report on Wednesday, June 24th. BTIG Research reaffirmed a “buy” rating and issued a $46.00 price target on shares of Maze Therapeutics in a report on Wednesday, August 12th. Wall Street Zen lowered Maze Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. Finally, TD Cowen upgraded shares of Maze Therapeutics to a “strong-buy” rating in a research note on Monday, August 24th. Three research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $66.00.

Maze Therapeutics Stock Down 0.2%

The firm has a fifty day simple moving average of $28.76 and a 200-day simple moving average of $31.49. The company has a market capitalization of $1.47 billion, a P/E ratio of -10.53 and a beta of 2.17. The company has a quick ratio of 18.31, a current ratio of 18.31 and a debt-to-equity ratio of 0.09.

Maze Therapeutics (NASDAQ:MAZE) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($0.76) earnings per share for the quarter, hitting the consensus estimate of ($0.76). On average, equities research analysts expect that Maze Therapeutics, Inc. will post -2.72 EPS for the current fiscal year.

Institutional Trading of Maze Therapeutics

A number of hedge funds have recently modified their holdings of the stock. California State Teachers Retirement System boosted its holdings in shares of Maze Therapeutics by 54,096.5% during the second quarter. California State Teachers Retirement System now owns 777,720 shares of the company’s stock worth $23,207,000 after acquiring an additional 776,285 shares during the period. Frazier Life Sciences Management L.P. raised its stake in Maze Therapeutics by 10.2% in the 2nd quarter. Frazier Life Sciences Management L.P. now owns 5,032,915 shares of the company’s stock worth $150,182,000 after purchasing an additional 465,641 shares in the last quarter. AXQ Capital LP boosted its holdings in Maze Therapeutics by 114.1% in the 2nd quarter. AXQ Capital LP now owns 15,193 shares of the company’s stock valued at $453,000 after purchasing an additional 8,098 shares during the period. Braidwell LP bought a new stake in Maze Therapeutics in the 2nd quarter valued at about $34,019,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in shares of Maze Therapeutics by 4,054.3% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 17,739 shares of the company’s stock worth $529,000 after purchasing an additional 17,312 shares during the period.

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.